ENVB
Enveric Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.41
+2.17%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +11.1%
- EBIT
- +12.4%
- EPS
- +99.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +7.1%
- EBIT
- +8.9%
- Net income
- -26.7%
- EPS
- +84.1%
- Free cash flow
- -5.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026